Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab completes recruitment for Phase II lymphoma study
Patients in this open label study will be randomized into two dose groups of 28 patients each and will receive a total of six infusions of ofatumumab in
Patients in this open label study will be randomized into two dose groups of 28 patients each and will receive a total of six infusions of ofatumumab in
Under the terms of the agreement, Qiagen will supply proprietary QIAplex-based reagents for the multiplex amplification of the most common viruses associated with respiratory infections. Qiagen has previously
Labopharm’s new drug application (NDA) for its novel antidepressant formulation containing trazodone is based on data from five pivotal pharmacokinetic studies and the positive results from its North
The purpose of the Phase III trial is to evaluate the safety and efficacy of unit dose budesonide (UDB) in approximately 360 children from 12 months to eight
Oxygen Biotherapeutics will receive stock in Glucometrics and running royalties on a sliding scale based on worldwide net revenues from products derived from the licensed technology. Under terms
The trial is a double-blind, placebo-controlled, dose-escalating clinical trial evaluating the safety and efficacy of the company’s topical drug candidate, RGN-137, in patients with venous stasis ulcers. There
As part of this potential $136 million development and commercialization collaboration, AstraZeneca and Dynavax have initiated investigational new drug enabling studies with AZD1419 and plan to begin Phase
This key Phase II/III trial data showed that LB03002 in children with growth hormone deficiency (GHD) demonstrates safety and efficacy profiles comparable with existing, daily human growth hormone
A double-blind placebo-controlled study was conducted in 100 patients with confirmed severe cholera. Patients were randomized to placebo or 125mg crofelemer every six hours or 250mg crofelemer every
The double-blind, placebo-controlled dose-escalating trial includes four groups of 10 subjects each to assess the safety of multiple doses at escalating concentrations of RGN-352 injected into the blood